Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 3, 2026

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

View original at finance.yahoo.com
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In 2024, there were nearly 14.5 million total diagnosed cases of CKD in the 7MM

    80% confidence

  • The CKD market size in the 7MM was approximately USD 4.8 billion in 2024 and is expected to increase further by 2034

    80% confidence

  • The CKD therapy market includes RAAS inhibitors as the standard of care and the rapidly growing use of SGLT-2 inhibitors such as FARXIGA and JARDIANCE as emerging front-line options

    80% confidence

  • The distribution of End-Stage Kidney Disease (ESKD) cases across the 7MM indicates that the number of patients on dialysis exceeds that of those receiving kidney transplants

    80% confidence

  • Zibotentan/dapagliflozin combination has the potential to reduce mortality and delay the onset of end-stage kidney disease (ESKD)

    80% confidence

  • Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment

    80% confidence

  • The United States accounts for the largest market size of chronic kidney disease, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan

    80% confidence

  • The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations

    80% confidence

  • KIM-1 and NGAL enable earlier, more precise detection of CKD than traditional methods, improving the potential for timely intervention and better patient outcomes

    80% confidence

  • Despite improved outcomes, current therapies only delay progression and cannot halt or reverse CKD, highlighting a major and persistent unmet need

    80% confidence

  • In 2024, there were approximately 82 million prevalent cases of CKD in the 7MM

    80% confidence

  • CKD cases are projected to increase further over the forecast period (2025-2034) due to the aging population

    80% confidence

  • No current medications can reverse CKD

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight — Source | Via News | ViaNews EU